Global Severe Acne Vulgaris Treatment Market Report and Forecast 2024-2032

Global Severe Acne Vulgaris Treatment Market Report

The severe acne vulgaris treatment market size attained a value of USD 10.30 billion in 2023, driven by the rising cases of severe acne vulgaris. The market is likely to grow further at a CAGR of 4.93% during the forecast period of 2024-2032 to reach a value of approximately 15.90 billion by 2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Introduction

Acne, or acne vulgaris, is a common skin condition that occurs when hair follicles are clogged with excessive production of sebum, dust, and dead skin cells. It is accompanied by acne, blackheads, blackheads, or scars.

Acne is divided into inflammatory acne and non-inflammatory acne. Acne treatments include removing dead skin cells, reducing oil production, and killing bacteria with medications and drugs.

Several studies have confirmed that acne can affect a person's quality of life, self-esteem, and mood. Acne is a chronic inflammatory skin disease with a multifactorial etiology. It is caused by hormonal changes during puberty and is exacerbated by genetics and other factors.

Acne medications include various prescription and over-the-counter medications, such as retinoids, isotretinoin, antibiotics, salicylic acid, benzoyl peroxide, and oral contraceptives.

The side effects of acne treatment vary on the choice and the power of medicine. The most common side effects are dry skin and irritation. The potential side effects of oral medications can be more serious. Antibiotics can upset your stomach and make you feel lightheaded or dizzy.

In addition, oral isotretinoin can cause serious side effects, especially if the patient becomes pregnant while taking it. Serious birth defects have been reported in infants whose mothers took isotretinoin during pregnancy. The drug may increase the risk of depression and suicide and may affect cholesterol levels and liver function. Safety issues related to acne products prevent the growth of global severe acne vulgaris treatment market.

Factors such as increasing prevalence of acne among teenagers and adults, increasing sedentary lifestyle and unhealthy eating habits, and increasing demand for minimally invasive cosmetic treatment procedures have propelled the demand and fuelled the market growth. However, safety concerns related to products used to treat acne are hindering the growth of the severe acne vulgaris treatment market.

According to the global severe acne vulgaris treatment research report, the market can be categorized into the following segments: 

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Breakup by Drugs

• Prescription Medicines

• Over-the-Counter Medicines

Market Breakup by Type

• Non-Inflammatory Acne

• Inflammatory Acne

Market Breakup by Treatment Method

• Systemic Therapy

• Hormonal Therapy
  • Oral Contraceptive
  • Spironolactone
  • Cyproterone Acetate
  • Flutamide

• Topical Antibiotics
  • Erythromycin
  • Clindamycin
  • Clarithromycin
  • Azithromycin
  • Nadifloxacin

• Topical Retinoids
  • Adapalene
  • Tazarotene
  • Tretinoin
  • Isotretinoin
  • Metretinide
  • Retinaldehyde
  • Beta-Retinoyl Glucuronide

• Physical Treatment
  • Lesion Removal
  • Phototherapy

• Topical Combination Therapy
  • Chemical Peeling
    • Glycolic Acids Peel
    • Salicylic Acid Peel
  • Pulsed Dye Laser Treatment
  • Others

Market Breakup by Age Group

• 10-17 years

• 18-40 years

• 40-65 years

• 65 and Above

Market Breakup by Distribution Channel 

• Derma Clinics

• Pharmacy

• E-Commerce

Market Breakup by Treatment Channel

• Public

• Private

Market Breakup by Region

• North America
  • United States of America
  • Canada
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
• Asia Pacific
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Others
• Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Increase Prevalence of Acne is Driving the Market Growth

Acne vulgaris is a common skin condition affecting the world population, with the highest prevalence among adolescents. It affects more men than women of all ethnic groups. Acne is the most common skin condition in the United States, affecting approximately 50 million Americans each year, according to the American Academy of Dermatology.

The increasing prevalence and severity of acne is driving the global acne vulgaris treatment market. Acne vulgaris is the most common acne disease with a significant psychological impact on adult female victims. About 80% of teenagers between the ages of 12 and 25 have acne. The indisposition of acne has led researchers to investigate the pathological factors of acne treatments. 

Additionally, technological advancements that offer fewer demanding features and proven results can be seen as future market opportunities to drive global severe acne vulgaris treatment market growth.

Increase in Expenditure on Cosmetic Products Driving the Severe Acne Vulgaris Treatment Market

The demand for minimally invasive cosmetic procedures is growing significantly worldwide. Dermatologists prefer to treat skin conditions with topical or minimally invasive procedures over surgical methods. Better informed decision-making, better patient-doctor relationships, and better-documented procedures will lead to increased demand for treatments for facial and skin problems. This has led to the adoption of less painful procedures for combined aesthetic therapy.

In addition, the increase in expenditure on cosmetic products and the increase in awareness of diseases among people are fuelling the growth of the global severe acne vulgaris treatment market.

North America is Dominating the Severe Acne Vulgaris Treatment Market

North America accounted for the largest share of the global market and is expected to maintain its dominance, owing to numerous advancements in acne treatments. However, Asia Pacific is expected to register the highest CAGR during the forecast period due to increased product launches, high demand for acne treatments and rising healthcare costs, and increased awareness of newly developed treatments.

Several factors such as unhealthy lifestyle, diet and smoking, hormonal changes and excessive sebum production have increased the prevalence of acne. Also, dermatological studies show that more people are affected by acne in Western societies, including North America. 

The burden of acne is widespread in North America and its prevalence has steadily increased with population growth. This continued expansion highlights dermatology's unmet needs and potential business opportunities to improve the accessibility and delivery of anti-acne medications.

Therapeutic Landscape

According to the expert, the development of acne treatments is currently focused on overcoming inflammation and redesigning the carriers of existing active drugs to increase efficacy and tolerability.

Over the counter (OTC) acne medications often contain benzoyl peroxide, salicylic acid, and sulphur. These medications come in a variety of forms, such as oral and topical formulations. OTC medications are primarily used in the mild acne population. Due to the prevalence of mild acne, there is a high demand for OTC medications. This will help the global severe acne treatment market grow at a rapid pace during the forecast period.

Topical benzoyl peroxide has a bactericidal effect against Cutibacterium acnes, an important component of acne vulgaris. Benzoyl peroxide is converted to benzoic acid when it is absorbed through the skin. About 5% of benzoic acid is absorbed and excreted by the renal system. 

The remaining benzoic acid is metabolised by cysteine in the skin, releasing active oxygen in free radicals and causing the oxidation of bacterial proteins. The improvement of acne vulgaris is achieved by reducing lipids, free fatty acids, and P. acnes.

Topical benzoyl peroxide also has a mild sebostatic effect, contributing to its keratolytic activity and effectiveness in the treatment of comedonal acne. Benzoyl peroxide effectively heals skin wounds by promoting the formation of healthy granulation tissue and rapid epithelial growth.

Clinical Trial 

In need to get a safer and more efficient treatment for severe acne vulgaris, researchers are modifying and reformulating drugs and are more drawn towards the study of combination treatment with new targeted therapies. Some of these clinical trials in the process are:

BioPharmX is developing a new proprietary topical minocycline gel formulation (BPX-01) for the treatment of acne vulgaris. This product is the company's first candidate for an anhydrous hydrophilic topical delivery system and minocycline is completely dissolved in our formulation. This formulation is currently in clinical development for patients with inflammatory acne vulgaris lesions.

Bausch Health Companies Inc. and dermatology company Ortho Dermatologics reported statistically significant top-line results in a second pivotal Phase 3 clinical trial evaluating the study drug IDP-126, a combination of a retinoid, antibacterial and antibiotic for the treatment of acne vulgaris in patients over 9 years of age.

Dermata Therapeutics DMT310 is a premium filter product developed based on the technology of the Spongilla platform. The unique filter product is derived from the natural source of Spongilla lacustris and contains multiple active ingredients to treat a variety of inflammatory skin conditions in a weekly application. It is currently in development for the treatment of moderate to severe acne, and mild to moderate psoriasis. It is currently being evaluated in Phase II. 

The demand for treatment will drive the global severe acne vulgaris treatment market.

Competitive landscape

The report gives an in-depth analysis of the key players involved in the global severe acne vulgaris treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows: 

• AbbVie, Inc (Allergen)

• Botanix Pharmaceuticals Ltd.

• Galderma S.A.

• Bausch Health Companies Inc.

• GlaxoSmithKline Plc.

• Johnson & Johnson Services Inc.

• Almirall S.A.

• Hospira, Inc.

• Viatris (Mylan N.V.)

• Sun Pharmaceutical Industries Ltd.

• Pfizer Inc.

• Teva Pharmaceutical Industries Ltd.

• Bayer AG

• Perrigo Company Plc.

• Boston Scientific Corporation (Lumenis)

Key Highlights of the Report

Severe Acne Vulgaris Treatment Market Report Snapshots

Severe Acne Vulgaris Treatment Market Size

Severe Acne Vulgaris Treatment Market Growth

Severe Acne Vulgaris Treatment Companies